Entrada Therapeutics price target lowered to $23 from $29 at Roth MKM
Roth MKM analyst Boobalan Pachaiyappan lowered the firm’s price target on Entrada Therapeutics (TRDA) to $23 from $29 and keeps a Buy rating on ...
Oppenheimer Reaffirms Their Buy Rating on Entrada Therapeutics Inc (TRDA)
In a report released today, Francois Brisebois from Oppenheimer reiterated a Buy rating on Entrada Therapeutics Inc (TRDA – Research Report), ...
MM&M5h
Rx Rundown: Thermo Fisher Scientific, the CDC, Eli Lilly and more
Rare Disease Day, an annual gathering hosted by the FDA and National Institutes of Health, was postponed. Medicare spending on 10 diabetes drugs, including popular GLP-1s, more than quadrupled over a ...
Managed Healthcare Executive3h
Duchenne Muscular Dystrophy: The Brain Is Affected Too
Researchers, physicians, families and affected patients view Duchenne muscular dystrophy (DMD) as a neuromuscular condition. Children are diagnosed during the first years of life because they have ...